Add to ORKGCombination of paclitaxel and carboplatin as second‐line therapy for patients with metastatic melanom
Background: The combination of paclitaxel and carboplatin has been used to treat patients with many ...
Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin p...
DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical st...
BACKGROUND: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic...
Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Ba...
There is no standard second-line regimen for malignant melanoma patients with disease progression af...
<p>Results of published studies on the combination of carboplatin and paclitaxel in patients with me...
The aim of this study was to investigate the activity and safety of a regimen containing carboplatin...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carci...
Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopha...
Metastatic melanoma has a median length of survival after diagnosis of 6–9 months. Unfortunately, th...
To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered ...
Aim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous do...
Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activi...
Background: The combination of paclitaxel and carboplatin has been used to treat patients with many ...
Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin p...
DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical st...
BACKGROUND: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic...
Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Ba...
There is no standard second-line regimen for malignant melanoma patients with disease progression af...
<p>Results of published studies on the combination of carboplatin and paclitaxel in patients with me...
The aim of this study was to investigate the activity and safety of a regimen containing carboplatin...
The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...
The combination of Carboplatin with Paclitaxel is the mainstay treatment for high-grade serous carci...
Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopha...
Metastatic melanoma has a median length of survival after diagnosis of 6–9 months. Unfortunately, th...
To determine the maximum-tolerated dose for the combination paclitaxel and carboplatin administered ...
Aim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous do...
Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activi...
Background: The combination of paclitaxel and carboplatin has been used to treat patients with many ...
Background – To evaluate the feasibility, efficacy, and toxicity of the combination of carboplatin p...
DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical st...